# Study to Evaluate Safety, Tolerability, and Pharmacokinetics of Idelalisib in Adults Receiving Ruxolitinib as Therapy for Primary, Post-Polycythemia Vera, or Post-Essential Thrombocythemia Myelofibrosis With Progressive or Relapsed Disease

> **NCT02436135** · PHASE1 · TERMINATED · sponsor: **Gilead Sciences** · enrollment: 10 (actual)

## Conditions studied

- Myelofibrosis

## Interventions

- **DRUG:** Idelalisib
- **DRUG:** Ruxolitinib

## Key facts

- **NCT ID:** NCT02436135
- **Lead sponsor:** Gilead Sciences
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2015-06-05
- **Primary completion:** 2017-11-20
- **Final completion:** 2017-11-20
- **Target enrollment:** 10 (ACTUAL)
- **Last updated:** 2020-09-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02436135

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02436135, "Study to Evaluate Safety, Tolerability, and Pharmacokinetics of Idelalisib in Adults Receiving Ruxolitinib as Therapy for Primary, Post-Polycythemia Vera, or Post-Essential Thrombocythemia Myelofibrosis With Progressive or Relapsed Disease". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT02436135. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*